Search This Blog

Friday, November 8, 2024

Autolus AUCATZYL OKd for relapsed/refractory B-cell acute lymphoblastic leukemia

 

  • AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
  • Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
  • Conference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release

Management will host a conference call and webcast on November 11 at 8:30 am EST/1:30 pm BST to discuss the AUCATZYL approval. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

https://www.globenewswire.com/news-release/2024/11/08/2977884/0/en/Autolus-Therapeutics-Announces-FDA-Approval-of-AUCATZYL-obecabtagene-autoleucel-obe-cel-for-adults-with-relapsed-refractory-B-cell-acute-lymphoblastic-leukemia-r-r-B-ALL.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.